Merck to Buy ArQule for $2.7 Billion, or $20/Share

Date : 12/09/2019 @ 12:26PM
Source : Dow Jones News
Stock : ArQule Inc (ARQL)
Quote : 20.0  0.0 (0.00%) @ 12:00AM

Merck to Buy ArQule for $2.7 Billion, or $20/Share

Merck (NYSE:MRK)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. (MRK) Monday said it agreed to buy ArQule Inc. (ARQL) for $20 a share in cash, for a total equity value of roughly $2.7 billion.

The purchase price is more than double Friday's closing price of $9.67 for ArQule, a Burlington Mass., biopharmaceutical company.

Shares of ArQule surged more than 100% to $19.45 in premarket trading.

Merck, a Kenilworth, N.J., drug maker known for the cancer drug Keytruda, said the deal expands its oncology pipeline into targeted therapies that treat hematological malignancies.

Merck said it expects to complete the acquisition early in the first quarter.


Write to Colin Kellaher at


(END) Dow Jones Newswires

December 09, 2019 07:11 ET (12:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ARQL Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.